The Earlier the Better: A New Approach for NK Diagnosis and -

Thank you for attending. The posttest will not be available immediately.

Note for ODs: COPE guidelines dictate that in order to receive credit, learners must remain present at the synchronous virtual activity until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.

Scroll back to top

Details

Overview
Management of neurotrophic keratitis (NK) is based on disease severity. This synchronous virtual symposium will focus on updated viewpoints on what truly constitutes stage 1 disease as well as NK diagnostic strategies, treatment of stage 1 NK to prevent progression, and a comparison of novel therapies to traditional approaches.
Note About Obtaining Credit:
You must attend the course in its entirety.
COPE guidelines dictate that in order to receive credit, learners must remain present at the synchronous virtual symposium until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.
This activity is supported by an unrestricted educational grant from Dompé.
Learning Objectives
Upon completion of this activity, the participant should be able to:
- Explain diagnostic strategies for neurotrophic keratitis (NK) and identify patients with stage 1 disease
- Describe current and emerging treatment options for stage 1 NK
- Develop personalized treatment plans for patients with stage 1 NK
- Discuss new data on novel treatments for NK and how it compares to traditional treatments
Accreditation
Provided by Evolve Medical Education
Evolve is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Evolve designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Evolve Medical Education, LLC is a COPE-accredited administrator.
This activity, COPE Activity Number 126606, is accredited by COPE for continuing education for optometrists. This course is approved for 1.0 hour of CE.
Course #: 86144-TD
Activity #: 126606
COPE advises optometrists to contact the State or Provincial Board where they are licensed for verification of what is acceptable for license renewal.
Participation Method
In order to obtain credit, proceed through the program, complete the posttest, evaluation and submit for credit.
Faculty and Disclosures
John A. Hovanesian, MD
Cornea and Cataract Specialist
Harvard Eye Associates
Laguna Hills, CA

Frank W. Bowden III, MD, FACS
Founder / Ophthalmologist
Bowden Eye and Associates
Jacksonville, FL

Jennifer Loh, MD
Founder, Loh Ophthalmology Associates
Clinical Faculty, Larkin Ophthalmology Residency Program
Board Member, Eye Physicians of Florida
Miami, FL

Kelly K. Nichols, OD, MPH, PhD, FAAO
University of Alabama at Birmingham
Professor and Dean of the School of Optometry
Birmingham, AL

DISCLOSURE POLICY
It is the policy of Evolve that faculty and other individuals who are in the position to control the content of this activity disclose any real or apparent financial relationships relating to the topics of this educational activity. Evolve has full policies in place that will identify and mitigate all financial relationships prior to this educational activity.
The following faculty/staff members have the following financial relationships with ineligible companies.
John A. Hovanesian, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Acufocus, Aerie Pharmaceuticals, Alcon, Allergan, Apellis, Avellino Labs USA, Azura Ophthalmics, Bausch + Lomb, BlephEx, Carl Zeiss Meditec, Cloudbreak Therapeutix, Cord, ECRI, Eyedetec, EyePoint, Glaukos, Glaxo Smithkline, Glint Pharma, Gobiquity, Guardion Health Sciences, Imprimis, Ingenoeye, Johnson & Johnson Vision, Kala Pharmaceuticals, MDbackline, Novartis, Ocular Therapeutix, Oculis, Omeros, On Point Vision, Orasis Pharmaceuticals, Oyster Point Pharma, Research InSight, Sensimed, Sight Sciences, SightLife, Sun Pharma, Tarsus Pharmaceuticals, TearLab, Touch Ophthalmology, Vindico Medical Education, and Visus. Grant/Research Support: Acufocus, Aerie Pharmaceuticals, Alcon, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Cord, EyePoint, Glaukos, Imprimis, Ingenoeye, Johnson & Johnson Vision, Novartis, Ocular Therapeutix, Omeros, On Point Vision, Research InSight, Sight Sciences, and Sun Pharma. Stock/Shareholder: Alcon, Alicia Surgery Center, Allegro Ophthalmics, Allergan, Cloudbreak Therapeutix, Cord, Corneagen, Crisper, Equinox, Eyedetec, Gobiquity, Guardion Health Sciences, Harvard Eye Associates, Ingenoeye, Johnson & Johnson Vision, MDbackline, Novartis, Ocular Therapeutix, Orasis Pharmaceuticals, Research InSight, RxSight, Sight Sciences, Tarsus Pharmaceuticals, TearClear, Versant Ventures and its investments, and Visionary Ventures Fund 1 and 2 and its investments. Royalties: Slack Books.
Frank W. Bowden III, MD, FACS, has had a finacial relationship or affiliation with the following ineligible companies in the form of Speaker's Bureau: Bausch + Lomb and Sun Pharma.
Jennifer Loh, MD, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: Alcon, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Centricity Vision, Dompé, Horizon, Johnson & Johnson Vision, Kala Pharmaceuticals, Lensar, Novartis, Omeros, Orasis Pharmaceuticals, OSRX, Sight Sciences, Sun Pharma, Tarsus Pharmaceuticals, and Visus. Grant/Research Support: Sight Sciences. Shareholder: Novabay. Speaker's Bureau: Alcon, Allergan, Bausch + Lomb, Sight Sciences, and Sun Pharma.
Kelly K. Nichols, OD, MPH, PhD, FAAO, has had a financial relationship or affiliation with the following ineligible companies in the form of Consultant: AbbVie, Aerie Pharmaceuticals, Alcon, Alderya, Allergan, Axim, Azura Ophthalmics, Bausch + Lomb, Bruder Healthcare, Cavalry, Dompé, HanAll Biopharma, Nicox, Novaliq, Novartis, Osmotica, Oyster Point Pharma, Palatin Technologies, RVL, Shire, Tarsus Pharmaceuticals, Takeda, TearSolutions, Théa Pharma, TopiVert, Trukera Medical, Verséa Health, and Xequel. Grant/Research Support: Aramis, Kowa, ScienceBased Health, TearScience, and Sylentis.
The Evolve staff, planners, and revieiwer have no financial relationships with ineligible companies.
Disclaimer
OFF-LABEL STATEMENT
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The opinions expressed in the educational activity are those of the faculty. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
DISCLAIMER
The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of Evolve or Dompé.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.
Note About Obtaining Credit:
You must attend the course in its entirety.
COPE guidelines dictate that in order to receive credit, learners must remain present at the synchronous virtual symposium until the end of the program. Attendees who meet the required instructional time established by COPE will receive an email with a link to obtain credit within 48 hours of the program's completion.
System Requirements
- Supported Browsers (2 most recent versions):
- Google Chrome for Windows, Mac OS, iOS, and Android
  Apple Safari for Mac OS and iOS
  Mozilla Firefox for Windows, Mac OS, iOS, and Android
  Microsoft Edge for Windows
- Recommended Internet Speed: 5Mbps+
Publication Dates
Expiration Date: 09/20/2023

Ready to Claim Your Credits?

You have attempts to pass this post-test. Take your time and review carefully before submitting.

Good luck!

Title

Share on ReachMD